About Vyne Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://vynetherapeutics.com/
Frequently Asked Questions
What is the 52-week range for YARW?
The 52-week high is $44.2757 and the 52-week low is $21.49.
What is the P/E ratio for YARW?
The P/E ratio data is currently unavailable.
What is the dividend yield for YARW?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -70.23%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3881.54%.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for YARW over the last few months:
Latest YARW News
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NEW HAVEN, Conn., September 14, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of its previously announced underwritten public offering of 6,634,615 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 865,384 additional shares, at a public offering price per share of $26.00.
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
NEW HAVEN, Conn., September 11, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its common stock at a public offering price per share of $26.00. The aggregate gross proceeds to Yarrow from the offering are expected to be approximately $150 million
Yarrow Bioscience Announces Proposed Underwritten Public Offering
NEW HAVEN, Conn., September 10, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Yarrow expects to grant the underwrit
Yarrow Bioscience Launches Underwritten Public Offering To Fund Pipeline Development And Corporate Operations; No Terms Disclosed
Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-29 | RTW Fund Group GP, LLC | +133,290 | - | - |
| 2026-07-29 | RTW Fund Group GP, LLC | -133,290 | - | - |
| 2026-07-27 | Ashiya Mona | +15,435 | - | - |
| 2026-07-27 | Zeronda Tyler | +185,798 | - | - |
| 2026-07-23 | Zeronda Tyler | -22,516 | $0.8976 | $20,210 |
| 2026-07-23 | Harsch Mutya | -22,516 | $0.8976 | $20,210 |
| 2026-07-23 | Domzalski David | -79,391 | $0.8976 | $71,261 |
| 2026-07-23 | Stuart Iain | -15,405 | $0.8976 | $13,828 |
| 2026-06-30 | Zeronda Tyler | -3,464 | $0.6507 | $2,254 |
| 2026-06-30 | Harsch Mutya | -3,464 | $0.6507 | $2,254 |
| 2026-06-30 | Domzalski David | -12,214 | $0.6507 | $7,948 |
| 2026-06-30 | Stuart Iain | -2,370 | $0.6507 | $1,542 |